
    
      The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic
      Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e.
      vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).
    
  